Dr Thomas Erblich is a Consultant Haematologist specialising in haemato-oncology, with a particular interest in lymphoma, chronic lymphocytic leukaemia and other lymphoid malignancies. He sees patients with suspected or confirmed blood cancers, abnormal blood counts, enlarged lymph nodes, MGUS, myeloma, lymphoma, CLL and related haematology conditions.

Alongside his private practice, Dr Erblich works as an NHS Consultant Haematologist at Queen Elizabeth Hospital, Lewisham & Greenwich NHS Trust. His clinical work includes the diagnosis, treatment and follow-up of patients with complex blood disorders, with a strong focus on malignant haematology. He offers consultations for self-pay and insured patients, including second opinions and comprehensive specialist cancer care.

Dr Erblich graduated from the Medical University of Vienna in 2006. He underwent specialist training at St Barts Hospital and certified in haematology in 2019, after which he undertook advanced academic and research training in lymphoma. He completed a clinical research fellowship in haemato-oncology and was awarded a PhD in 2024 for his work in lymphoma research. His doctoral research focused on liquid biopsy approaches, including circulating tumour DNA, to better understand and monitor lymphoma over time. Since 2024 he is a consultant at Queen Elizabeth Hospital.

His research background gives Dr Erblich a detailed understanding of modern lymphoma diagnostics, disease monitoring and personalised cancer care. He combines this academic expertise with day-to-day clinical experience, helping patients understand complex diagnoses and make informed decisions about their treatment.

Dr Erblich has published academic research in haematology and lymphoma and remains actively involved in clinical research, service development and innovation. He has experience in clinical trials and biomarker research and is a member of the National Lymphoma Network Scientific Subgroup, contributing to wider developments in lymphoma care across the UK.

In his clinical practice, Dr Erblich sees patients with a broad range of blood disorders, with a particular interest in lymphoma, CLL, myeloma, and related haematological cancers. Patients can expect a careful, clear and individualised approach. Dr Erblich takes time to explain the diagnosis, the likely course of the condition, and the available treatment options in plain language. His aim is to help patients feel informed, supported and confident in their care plan.
He has a particular interest in helping patients navigate uncertainty. This may include assessing whether a condition needs immediate treatment, whether careful monitoring is appropriate, or whether further diagnostic tests are required. He is also experienced in providing second opinions for patients who would like an expert review of their diagnosis or treatment plan.

Dr Erblich works closely with multidisciplinary teams, including specialist nurses, radiologists, pathologists, oncologists and other haematology colleagues. This team-based approach is especially important in lymphoma and CLL, where diagnosis and treatment decisions often depend on combining clinical findings with imaging, pathology, molecular tests and patient preference.

His clinical approach is evidence-based, but also personal. He recognises that patients often come to a haematology appointment at a stressful and uncertain time. He aims to provide clear explanations, realistic advice and a calm environment in which patients can ask questions and understand their options.

“My aim is to combine specialist expertise in lymphoma and blood cancers with clear, compassionate communication, so that patients understand their diagnosis and feel supported in making the right decisions for them.”

Dr Erblich is a member of the Royal College of Physicians, the Royal College of Pathologists, the British Society for Haematology and the European Hematology Association.
He speaks English and German fluently. He also has basic Mandarin language skills.

Clinical Interests

• Lymphoma
• CLL
• Myeloma
• Related haematological cancers

• Royal College of Physicians
• Royal College of Pathologists
• British Society for Haematology
• European Haematology Association